Skip to main content
Premium Trial:

Request an Annual Quote

AviaraDx, Mass General Cancer Center to Co-Develop Dx for Targeted Cancer Drugs

NEW YORK, May 17 (GenomeWeb News) - AviaraDx, formerly known as Arcturus Bioscience, and Massachusetts General Hospital Cancer Center plan to identify molecular profiles for multiple types of cancer, and hope to develop diagnostics that could help predict the way a patient may respond to certain targeted cancer drugs.

 

Over the next two years, researchers at MGH and AviaraDx will perform gene sequencing and gene expression analysis on a "large number" of cancers to determine genes, gene signatures, and polymorphisms that correlate with response to specific drugs used for a "wide range" of cancers.

 

Financial terms of the deal were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.